Solid biosciences announces appointment of iman barilero, pharmd, ph.d., as chief regulatory officer

Cambridge, mass., june 07, 2021 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced that dr. iman barilero has joined the company as chief regulatory officer, effective june 1, 2021.

SLDB Ratings Summary

SLDB Quant Ranking